NEWS | BEAM Alliance


Polyphor’s antibiotic murepavadin receives US FDA Qualified Infectious Disease Product designation in four new indications

Allschwil, Switzerland, April 12, 2019

Polyphor AG (SIX: POLN) today announced that the US Food and Drug Administration (FDA) has designated murepavadin as a Qualified Infectious Disease Product (QIDP) in four additional indications; hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infection, bloodstream infection and complicated intra-abdominal infection.

Full PR available here